Baltimore-based Guilford Pharmaceuticals Inc. said yesterday that it has received government regulatory approvals to market its Gliadel treatment for malignant brain cancer in Canada and France.
The Canadian Health Protection Branch and the French Drug Agency approved Gliadel for use in treating glioblastoma multiforme, a rapidly growing and one of the most fatal forms of brain cancer.
Gliadel is a thin, dime-sized wafer that is loaded with a potent anti-cancer agent. Surgeons implant the wafers into cavities left in the brain after surgery to remove tumors. The anti-cancer drug is released as the wafer dissolves, slowing re-growth of tumors.
Gliadel has been marketed in the United States since late 1996, when it was approved by the Food and Drug Administration.
Drug giant Rhone-Poulenc Rorer bought worldwide marketing rights to the product and pays Guilford royalties on sales.
Under its agreement, Guilford said it will receive milestone payments from Rhone-Poulenc of $2 million and $2.5 million respectively for the Canadian and French approvals.
Pub Date: 12/23/98